Bristol-Myers Squibb (United Kingdom)

Real-World Effectiveness of Mavacamten in Canada: Insights from the MAVEN Study

Previous studies have demonstrated the efficacy and safety of mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), primarily outside of Canada, with limited Canadian real-world data evidence. The MAVEN study aimed to describe the real-world effe...

Treatment patterns and clinical outcomes in patients with loco-regional recurrent melanoma in the United Kingdom

Limited guidance exists for the treatment of loco-regional recurrence of melanoma, particularly in the context of emerging use of immunotherapies in the adjuvant setting. Additionally, outcomes are not well known among patients. Thus, the aim of this study was to describe real-wo...

Structure-Based Design of 2-(Pyridone)Indoles as Antagonists of the Toll-Like Receptors TLR7 and TLR8 for the Treatment of Autoimmune Disorders

Abstract Toll-like receptors 7 and 8 (TLR7/8) are innate immune sensors whose activation by endogenous RNA ligands is a hallmark of chronic autoimmune disorders, notably cutaneous and systemic lupus. We present the structure-based design and optimization of 2-(pyridin-2(1H)-one)i...

Inequalities in oral anticoagulant treatment patterns: a two-part model to estimate healthcare costs associated with atrial fibrillation

Abstract Background Atrial fibrillation (AF) is a common cardiac rhythm disorder associated with an increased risk of stroke, contributing to high healthcare costs. Oral anticoagulants (OACs) are well established in the management of AF, failure to initiate treatment and disconti...

Real-World Use of Adjuvant Nivolumab for Resected Stage III–IV Melanoma: 2-Year Analysis of AdjuMel

Following the positive findings of the phase 3 CheckMate 238 trial, adjuvant nivolumab has become a standard therapy in patients with completely resected stage III–IV melanoma. The prospective, ongoing AdjuMel study is evaluating the real-world use, effectiveness, and safety of a...